Dr. Tian Wenzhi is Chairman of the Board, CEO, CSO and Executive Director of the Group, overseeing overall strategic planning, business management and R&D. He founded the Group in June 2015, assumed his current core roles since 2015-2018. With over 30 years in biomedicine, Dr. Tian previously held roles at Weill Cornell Medical College, ImClone Systems (antibody drug R&D), and Huabo Biopharm (GM, 2011-2015). A senior biomedical engineer (Shanghai, 2019), he is a visiting/distinguished professor at Zhengzhou University affiliates and Fudan University. Dr. Tian holds a bachelor’s (medicine) and master’s (immunology) from Zhengzhou University (equivalent to US MD and master’s per WES), completed postdoctoral training at North Shore University Hospital (US), and researched at Karolinska Institute. He has 32 publications, 1 monograph contribution and 28 issued patents.